CLNN Earnings Date: Nov 12, 2026 (Estimated) — Clene Inc.
NASDAQ · Consumer Staples · Packaged Foods
Updated
When is CLNN's next earnings date?
Clene Inc. (CLNN) is expected to report Q3 2026 earnings on Thursday, November 12, 2026 at 8:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.46 on revenue of $70,000.
How did CLNN do in its last earnings report?
In its most recent report on Aug 14, 2026 (Q2 2026), Clene Inc. posted EPS of -$1.08 versus the -$0.37 estimate, a miss of 285.7%. Revenue was $90,000 against a $61,000 estimate. The stock's 1-day post-earnings move was -1.2%.
How much does CLNN stock move after earnings?
CLNN beat EPS estimates in 2 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 9.7% (up or down) in the day after earnings.
About Clene Inc.
Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nanotechnology (CSN). CNM-Au8 stands as its flagship compound, currently under evaluation across a diverse range of clinical studies. This includes a pivotal Phase 2/3 study intended for regulatory submission in individuals battling amyotrophic lateral sclerosis (ALS). The company has successfully concluded a Phase 2 proof-of-concept trial for those with early manifestations of ALS. Furthermore, two open-label, investigator-blinded Phase 2 trials assessing brain energy metabolism have been finished. An ongoing Phase 2 trial is investigating CNM-Au8's potential to mitigate visual pathway deficits stemming from chronic optic neuropathy, aiming for remyelination in stable relapsing Multiple Sclerosis patients. A Phase 2 clinical investigation targeting Parkinson's Disease patients is also slated for commencement. Beyond its leading candidate, Clene's pipeline extends to include CNM-AgZn17. This gel formulation, comprising silver and zinc ions, is in development to combat infectious diseases and hasten wound recovery. Additionally, CNM-ZnAg acts as a broad-spectrum antiviral and antibacterial compound, designed to address various infectious conditions like COVID-19, while also offering immune support for symptom alleviation. For oncology, CNM-PtAu7 is a gold-platinum CSN therapeutic agent currently in development. The company also distributes dietary supplements, featuring rMetx, a liquid supplement containing zinc-silver ions, and KHC46, an aqueous gold supplement with trace amounts of gold nanoparticles. Clene Inc. maintains its headquarters in Salt Lake City, Utah.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-14 | Q2 2026 | -0.37 | -1.08 | -285.71% | $90,000 | ❌ Miss | -1.19% | +3.58% | -21.72% |
| 2026-05-14 | Q1 2026 | -0.66 | -0.69 | -4.55% | $15,000 | ❌ Miss | +8.46% | +6.15% | -10.15% |
| 2026-03-12 | Q4 2025 | -0.55 | -0.88 | -60.00% | $77,000 | ❌ Miss | +6.09% | +17.74% | +9.50% |
| 2025-11-13 | Q3 2025 | -0.58 | -0.85 | -46.55% | $15,000 | ❌ Miss | -22.42% | -8.08% | -28.06% |
| 2025-08-14 | Q2 2025 | -0.47 | -0.78 | -65.96% | $27,000 | ❌ Miss | -1.37% | +53.97% | +58.90% |
| 2025-03-24 | Q4 2024 | -0.87 | -1.67 | -91.95% | $91,000 | ❌ Miss | -5.31% | -22.22% | -28.02% |
| 2024-11-13 | Q3 2024 | -1.32 | -1.22 | +7.58% | $87,000 | ✅ Beat | -9.06% | -12.08% | -6.42% |
| 2024-08-07 | Q2 2024 | -1.60 | -1.06 | +33.75% | $91,000 | ✅ Beat | -23.47% | -13.78% | +7.31% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $90K total
| Segment | Share | Revenue | YoY | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 |
|---|---|---|---|---|---|---|---|
| Product | 82.2% | $74K | — | $64K | $65K | $64K | $64K |
| Royalty | 17.8% | $16K | — | $27K | $22K | $27K | $17K |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.